Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GILEAD SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 78.32 USD | -1.30% | +2.61% | -8.44% | |
| Dec. 06 | Transgene: new CFO, share price rises | CF |
| Dec. 04 | IDEAYA Biosciences Collaborates With Gilead Sciences to Evaluate Combination of Trodelvy, IDE397 for Bladder Cancer | MT |
Financials (USD)
| Sales 2023 * | 27.05B | Sales 2024 * | 27.61B | Capitalization | 98.89B |
|---|---|---|---|---|---|
| Net income 2023 * | 5.89B | Net income 2024 * | 6.66B | EV / Sales 2023 * | 4,20x |
| Net Debt 2023 * | 14.76B | Net Debt 2024 * | 9.78B | EV / Sales 2024 * | 3,94x |
| P/E ratio 2023 * | 16,9x | P/E ratio 2024 * | 14,6x | Employees | 17,000 |
| Yield 2023 * | 3,81% | Yield 2024 * | 4,01% | Free-Float | 99.88% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -0.79% | ||
| 1 week | +2.55% | ||
| Current month | +2.55% | ||
| 1 month | -2.56% | ||
| 3 months | +6.23% | ||
| 6 months | +3.25% | ||
| Current year | -8.50% |
1 week
76.20
80.18
1 month
73.9980.18
Current year
72.8788.29
1 year
72.8789.74
3 years
56.5689.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 53 | 2015 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 2021 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 68 | 2020 |
| Director/Board Member | 70 | 2017 | |
Kevin Lofton
BRD | Director/Board Member | 68 | 2009 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 323 M€ | -7.87% | - | |
| 8.71% | 396 M€ | -3.41% | ||
| 8.14% | 15 M€ | -5.36% | ||
| 8.10% | 0 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-07 | 78.54 | -1.03% | 3 057 594 |
| 23-12-06 | 79.36 | +0.43% | 5,745,464 |
| 23-12-05 | 79.02 | +0.87% | 6,277,013 |
| 23-12-04 | 78.34 | +0.89% | 8,194,691 |
| 23-12-01 | 77.65 | +1.37% | 5,400,471 |
Delayed Quote Nasdaq, December 07, 2023 at 10:55 am EST
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
79.36USD
Average target price
90.39USD
Spread / Average Target
+13.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.50% | 98 886 M $ | |
| +58.87% | 530 B $ | |
| +41.81% | 438 B $ | |
| -12.20% | 377 B $ | |
| -6.34% | 268 B $ | |
| -9.16% | 258 B $ | |
| -14.20% | 230 B $ | |
| +0.61% | 200 B $ | |
| -10.39% | 198 B $ | |
| -44.32% | 163 B $ |
